Mylan Inc. is launching morphine sulfate extended-release tablets, an opioid analgesic for the treatment of moderate to severe pain.


Mylan, Mylan Pharmaceuticals, morphine sulfate extended-release tablets, Morphine sulfate ER tablets, generic version of MS Contin, Purdue Pharma, opioid analgesic, treatment of moderate to severe pain, pain management, prescription medication






































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Mylan ships generic version of MS Contin

October 28th, 2011

PITTSBURGH – Mylan Inc. is launching morphine sulfate extended-release tablets, an opioid analgesic for the treatment of moderate to severe pain.

The company said its Mylan Pharmaceuticals Inc. subsidiary has received final approval from the Food and Drug Administration for morphine sulfate ER tablets in strengths of 15 mg, 30 mg, 60 mg, 100 mg and 200 mg. The prescription medication is shipping immediately.

According to Mylan, the product is the generic version of Purdue Pharma's MS Contin medication for pain management.

Morphine sulfate ER tablets had U.S. sales of about $173 million for the 12 months ended June 30, according to IMS Health figures reported by Mylan.

Advertisement